Contact
Please use this form to send email to PR contact of this press release:
Defender Pharmaceuticals Reports Positive Results from Pivotal Phase III Clinical Trial of Intranasal Scopolamine for the Prevention of Nausea and Vomiting Induced by Motion
TO: